Antibodies News and Research

RSS

Blocking the COX-1 enzyme might prevent and treat the most common and fatal form of ovarian cancer

Blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer, researchers at Vanderbilt University Medical Center reported this week.

1 May 2005

Promising new West Nile therapy cures disease in mice

West Nile virus alarmed Americans when it made its first U.S. appearance in New York City in 1999. It has since spread from coast to coast, sickened more than 16,000 Americans and killed more than 600.

27 Apr 2005

Angiogenesis : Blocking tumor growth and treating infarction - a new target

Our tissues are able to form new blood vessels throughout life. This mechanism, which is called angiogenesis, is essential notably in the case of myocardial infarction, stroke and limb ischemia. The very same mechanism, however, keeps tumors supplied with nutrients and oxygen thus enabling them to continue growing.

27 Apr 2005

Australian researchers develop West Nile virus treatment

A University of Queensland researcher has developed the world's first specific immunotherapy product using monoclonal antibodies for the potentially lethal West Nile virus, which causes seasonal epidemics around the globe.

26 Apr 2005

Antibody for West Nile virus shows promise

Researchers have developed an antibody that can cure mice of West Nile virus (WNV) infection, a disease for which no specific treatment exists, the National Institute of Allergy and Infectious Diseases (NIAID) has announced.

25 Apr 2005

Scientists weaponize an antibody to deliver continuous attacks on cancer cells

In a recent study published in Molecular Cancer Therapeutics, researchers at the Weizmann Institute of Science paired the active ingredient of a garden remedy with advanced bio-technology to deliver a powerful punch against cancer. The cancer killing effectiveness lies in their technique of arming a cancer-targeting antibody with the destructive potential of the dietary molecule otherwise known as "allicin."

22 Apr 2005

Cancer patients may one day benefit from treatment with mixtures of customized antibodies

In a study published recently in the Proceedings of the National Academy of Sciences (USA), a team of Weizmann Institute scientists have demonstrated how the right combination might form a web that destroys the cancer cell's communication network, ultimately demobilizing the cell.

22 Apr 2005

Experimental vaccine targeting West Nile virus

A small trial testing the safety of an experimental vaccine targeting West Nile virus (WNV) opened today at the National Institutes of Health's (NIH) Clinical Center in Bethesda, MD.

19 Apr 2005

Allergic diseases have increased

The rate of allergic diseases (atopy) in adults has steadily increased over the last quarter of the 20th century, but the reason for the increase is still unknown, according to a study published online by the BMJ.

19 Apr 2005

Researchers discover mechanism by which tumours support their own growth

In a recent issue of the American Journal of Pathology, the Bremen researchers report their findings on a signalling molecule called "High Mobility Group Protein B1" (HMGB1). As a signal sent by tumour cells HMGB1 proteins induce sprouting of blood vessels that supply tumours with oxygen, thus promoting tumour growth.

11 Apr 2005

Increased scrutiny of new multiple sclerosis-fighting drugs after Tysabri withdrawal

The removal of Tysabri from the market soon after its introduction is expected to increase scrutiny of other similar drugs in development for multiple sclerosis (MS), says ECRI, a leading, independent health services research agency.

11 Apr 2005

Malaria's secret weapon revealed

A US-led international team of scientists have discovered how the deadliest malaria parasite is able to "hide" from the body's immune system.

10 Apr 2005

Research helps understand how the malaria parasite disguises itself to avoid detection by the immune system

Scientists are making strides in understanding how the malaria parasite Plasmodium falciparum disguises itself to avoid detection by the immune system. The findings could lead to the development of new drugs for a disease that causes more than 300 million acute illnesses and at least one million deaths each year, most of them in developing countries.

7 Apr 2005

Infection with Chlamydia pneumoniae may increase the risk of heart attack in young men

Preliminary research suggests infection with Chlamydia pneumoniae may increase the risk of heart attack in young men, according to an article in the April 15 issue of Clinical Infectious Diseases.

7 Apr 2005

Epstein-Barr virus may increase risk of lupus

Almost everyone has been infected with Epstein-Barr virus (EBV), a member of the herpes family and one of the most common human viruses.

7 Apr 2005

EvoGenix expands capabilities through US acquisition

EvoGenix and Absalus own complementary technologies which, when combined, are capable of streamlining the identification of new antibody drug candidates and improving the development of safe and effective human therapeutic antibodies.

4 Apr 2005

Infants under one year of age can accept heart transplants from donors of different blood groups

A study showing that infants under one year of age can accept heart transplants from donors of different blood groups without the risk of organ rejection means a better chance of survival for infant patients and more efficient use of donor organs overall.

4 Apr 2005

Unravelling the Ebola virus’s biological cycle

Ebola virus infection in humans provokes a violent haemorrhagic fever. It usually flares up as intense epidemics. These kill 80 % of the people infected. Seven such outbreaks have hit Gabon and the Republic of Congo since 1994, leading to 445 cases resulting in 361 deaths.

4 Apr 2005

Tarvacin shows significant anti-viral activity

Peregrine Pharmaceuticals today announced that there will be two presentations, April 4 and 6, at the American Association of Immunologists (AAI) annual meeting in San Diego, California, indicating the anti-viral potential of its Tarvacin antibody. Dr. Melina Soares of The University of Texas Southwestern Medical Center at Dallas will present pre-clinical data titled "Targeting inside-out phospholipids on viruses in a guinea pig model of Lassa fever."

4 Apr 2005

Tumour Necrosis Factor alpha (TNF-alpha) blocking agents cause skin disease

Members of the second most important family of drugs used to treat rheumatoid arthritis can cause serious dermatological conditions in a quarter of patients under treatment, reveals a study published in the journal Arthritis Research and Therapy.

3 Apr 2005